TriveniBio
PrivateLast Round
Series C
Jun 17, 2026
Est. Valuation
$390.53M
Total Funding Raised
$272M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
TriveniBio is a clinical-stage biotechnology company developing novel antibody-based therapies for immunological and inflammatory disorders using a genetics-informed approach.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TriveniBio Comparables
Compare TriveniBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Roche Holding | 75% | |
| Bionyra Pharma | 74% | |
| AbbVie | 74% | |
TriveniBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 17, 2026 | ||||
| Series B | Oct 2, 2024 | ||||
| Series A | Oct 26, 2023 |
Key People
Founding team and executive leadership
TriveniBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| Fidelity Management & Research Company | Series B |
| Deep Track Capital | Series C, Series B |
| OrbiMed | Series B, Series A |
| Cormorant Capital | Series A |
| Invus Opportunities | Series B, Series A |
| Viking Global Investors | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
$65M round led by Janus Henderson Group and Ascenta Capital
- Nov 1, 2025
Developing an IL-13 targeting asset for atopic dermatitis.
TriveniBio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about TriveniBio's valuation, stock price, and market status.